Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common drug replace surgery for pituitary tumors?

NCT ID NCT02288962

Disease control Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether cabergoline, a drug already used for hormone-producing pituitary tumors, can shrink or slow the growth of non-functioning pituitary adenomas (NFPAs). These tumors do not produce excess hormones, so current treatment is limited to surgery or radiation, which carry risks. The study enrolls adults with untreated or residual NFPAs and measures tumor volume changes over two years using MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabergoline, a dopamine agonist drug
What this could lead to
If effective, cabergoline could become the first drug treatment for non-functioning pituitary adenomas, reducing the need for repeated surgeries or radiation.
What could go wrong
This is a small phase 3 trial with 60 participants, and previous evidence is limited to non-randomized studies. Cabergoline may not shrink tumors in all patients and carries a risk of heart valve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2014

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A previously untreated non-functioning pituitary macroadenoma (largest diameter ≥ 10 mm) with either demonstrated growth on repeated MRI scans or ≤ 2 mm distance to chiasma opticum, or: * a residual non-functioning pituitary adenoma after surgery (largest diameter ≥ 5 mm) that is either extrasellar and/or with documented growth after surgical treatment of a non-functioning pituitary macroadenoma Exclusion Criteria: * Clear indication for surgery at the time of inclusion * Previous radiation therapy * Pituitary surgery the last 6 months * Previous apoplexy/bleeding in the adenoma * Pregnancy or lactation * Contraindications for cabergoline treatment (Known cardiac valvular disease, known pulmonal, pericardial or retroperitoneal fibrosis, clinical significant liver insufficiency, use of medications that interact with cabergoline * unfit to participate due to any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoma non-functioning pituitary adenoma Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenoma Pituitary neoplasms

Contacts and locations

Locations

  • Department of Endocrinology, Akershus University hospital

    Oslo, Norway

  • Department of Endocrinology, St. Olavs Hospital

    Trondheim, 7006, Norway

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.